Novel indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2020221824A1
Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
WO2020221816A1
Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
WO2020221811A1
Novel oxalyl piperazines active against the hepatitis b virus (hbv)
TW202031660A
Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv)
WO2020089459A1
Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv)
WO2020089452A1
Novel urea 6,7-dihydro-4h-pyrazolo[4,3-c]pyridines active against the hepatitis b virus (hbv)
TW202031659A
Novel 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2020089460A1
Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv)
WO2020089453A1
Novel 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
AU2019304526A1
Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
CA3081386A1
Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
KR20200083552A
New highly active pyrazolo-piperidine substituted indole-2-carboxamide active against hepatitis B virus (HBV)
TW201919675A
Combination therapies of hepatitis B virus (HBV)-infected individuals using Parapoxvirus ovis (PPVO) and at least one further antiviral drug
AU2017365639A1
A maleate salt of the free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof for the treatment of herpes viruses
EP3544976A1
N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof
WO2015121413A1
New active pharmaceutical ingredient combinations with compounds based on tri(hetero)aryl pyrazoles
WO2014202737A1
Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
SG11201506153TA
Helicase-primase inhibitors for use in a method of treating alzheimer's disease
US2014193802A1
Identification of an altered therapeutic susceptibility to anti-hcmv compounds and of a resistance against anti-hcmv compounds
